ID: ALA195538

Max Phase: Preclinical

Molecular Formula: C17H17FO

Molecular Weight: 256.32

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc(/C=C\c2ccc(C)c(C)c2)cc1F

Standard InChI:  InChI=1S/C17H17FO/c1-12-4-5-14(10-13(12)2)6-7-15-8-9-17(19-3)16(18)11-15/h4-11H,1-3H3/b7-6-

Standard InChI Key:  ALTBQLFTBMFPSU-SREVYHEPSA-N

Associated Targets(Human)

Tubulin beta-1 chain 182 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 256.32Molecular Weight (Monoisotopic): 256.1263AlogP: 4.62#Rotatable Bonds: 3
Polar Surface Area: 9.23Molecular Species: NEUTRALHBA: 1HBD: 0
#RO5 Violations: 0HBA (Lipinski): 1HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 5.32CX LogD: 5.32
Aromatic Rings: 2Heavy Atoms: 19QED Weighted: 0.73Np Likeness Score: -0.73

References

1. Ducki S, Mackenzie G, Lawrence NJ, Snyder JP..  (2005)  Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly.,  48  (2): [PMID:15658859] [10.1021/jm049444m]

Source